US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Franklin Genomic Advancements ETF

43.36

+1.022.41%

Post-market: 43.28-0.0858-0.20%19:30 EDT

Volume:513

Turnover:22.27K

Market Cap:32.52M

PE:- -

High:43.40

Open:43.40

Low:43.28

Close:42.34

52wk High:43.40

52wk Low:29.50

Shares:750.00K

Float Shares:750.00K

Volume Ratio:0.75

T/O Rate:0.07%

Dividend:0.14

Dividend Rate:0.33%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Guardant Health is Maintained at Overweight by Morgan Stanley

Analysts Are Bullish on These Healthcare Stocks: Natera (NTRA), Ionis Pharmaceuticals (IONS)

Adaptive Biotechnologies is Maintained at Equal-weight by Morgan Stanley

Natera Shares Gain 2.8% After EU Certification for Cancer Test

THOMSON REUTERS

How New Signatera Colorectal Data and Trial Deals Could Shape Natera’s (NTRA) Long-Term Narrative

Simply Wall St.

Ligand Pharmaceuticals : Bofa Global Research Raises Price Objective to $388.00 from $266.00

THOMSON REUTERS

Adaptive Biotechnologies price target raised to $20 from $18 at Morgan Stanley

Guardant Health price target raised to $175 from $130 at Morgan Stanley

Ligand price target raised to $388 from $266 at BofA

Natera Announces Ivdr Certification for Signatera™ Across Multiple Cancers

THOMSON REUTERS

Natera’s Signatera MRD Test Wins EU IVDR Certification for Multiple Cancers

Natera Executive Chairman Matthew Rabinowitz Reports Disposal of 1,000 Common Shares Worth $280,000

Guardant Health is Maintained at Buy by Citigroup

Ligand Pharmaceuticals Inc : Stifel Raises Target Price to $332 from $255

THOMSON REUTERS

Guardant Health price target raised to $215 from $150 at Citi

Adaptive Biotech CSO Harlan S. Robins Disposes of USD 8.49 Million in Common Shares

Natera President, Clinical Diagnostics Solomon Moshkevich Disposes of USD 819,636 in Common Shares

Does Russell Index Removal Reshape the Bull Case for Adaptive Biotechnologies (ADPT)?

Simply Wall St.

Adaptive Biotechnologies CCO Susan Bobulsky Sells 487 Shares Worth $10,714

Ligand CLO, Secretary Andrew Reardon Disposes of Common Shares Worth $1.53 Million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/HELX/news?page=10"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"HELX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELX\",,,,,undefined,":{"symbol":"HELX","market":"US","secType":"STK","nameCN":"Franklin Genomic Advancements ETF","latestPrice":43.3608,"timestamp":1787688000000,"preClose":42.3399,"halted":0,"volume":513,"hourTrading":{"tag":"盘后","latestPrice":43.275,"preClose":43.3608,"latestTime":"19:30 EDT","volume":7,"amount":303.5256,"timestamp":1787700600805,"change":-0.0858,"changeRate":-0.001979,"amplitude":0},"delay":0,"changeRate":0.02411200782240859,"floatShares":750000,"shares":750000,"eps":0,"marketStatus":"Closed","change":1.0209,"latestTime":"08-25 16:00:00 EDT","open":43.4001,"high":43.4001,"low":43.275,"amount":22270.999302,"amplitude":0.002955,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787731200000},"marketStatusCode":5,"adr":0,"exchange":"CBOE","adjPreClose":42.3399,"sharesOutstanding":650000,"nav":42.572,"aum":31928918.45,"dividendRate":0.003321,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":43.275,"preClose":43.3608,"latestTime":"19:30 EDT","volume":7,"amount":303.5256,"timestamp":1787700600805,"change":-0.0858,"changeRate":-0.001979,"amplitude":0},"volumeRatio":0.751318,"impliedVol":0.0938,"impliedVolPercentile":0.3665},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELX\",,,,,undefined,":{"symbol":"HELX","floatShares":750000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.751318,"shares":750000,"dividePrice":0.144,"high":43.4001,"amplitude":0.002955,"preClose":42.3399,"low":43.275,"week52Low":29.5,"pbRate":"--","week52High":43.4001,"institutionHeld":0,"latestPrice":43.3608,"eps":0,"divideRate":0.003321,"volume":513,"delay":0,"ttmEps":0,"open":43.4001,"prevYearClose":36.3062,"prevWeekClose":43.11,"prevMonthClose":38.8312,"prevQuarterClose":39.9651,"fiveDayClose":40.9918,"twentyDayClose":39.1286,"sixtyDayClose":34.2035},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HELX\",params:#limit:5,,,undefined,":[{"date":"2025-12-30","symbol":"HELX","amount":0.14334,"announcedDate":"2025-12-29","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-30","defaultRemindTime":1767105000000,"name":"Franklin Genomic Advancements ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-08","payableDate":"2025-12-30","currency":"USD","dateTimestamp":1767070800000,"payDate":"2026-01-08"},{"market":"US","date":"2021-12-30","symbol":"HELX","amount":0.003935,"defaultRemindTime":1640874600000,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2022-01-07","payableDate":"2021-12-31","currency":"USD","type":"dividend","dateTimestamp":1640840400000},{"market":"US","date":"2021-12-13","symbol":"HELX","amount":0.114148,"defaultRemindTime":1639405800000,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2021-12-21","payableDate":"2021-12-14","currency":"USD","type":"dividend","dateTimestamp":1639371600000},{"market":"US","date":"2020-12-14","symbol":"HELX","amount":0.005005,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2020-12-23","payableDate":"2020-12-15","currency":"USD","type":"dividend","dateTimestamp":1607922000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HELX\",market:\"US\",,,undefined,":[{"executeDate":"2020-12-14","recordDate":"2020-12-15","paymentDate":"2020-12-23","value":0.005005,"currency":"USD"},{"executeDate":"2021-12-13","recordDate":"2021-12-14","paymentDate":"2021-12-21","value":0.114148,"currency":"USD"},{"executeDate":"2021-12-30","recordDate":"2021-12-31","paymentDate":"2022-01-07","value":0.003935,"currency":"USD"},{"executeDate":"2025-12-30","recordDate":"2025-12-30","paymentDate":"2026-01-08","value":0.14334,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HELX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HELX\",pageSize:20,pageCount:10,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2650976358","title":"Guardant Health is Maintained at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2650976358","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650976358?lang=en_us&edition=fundamental","pubTime":"2026-07-10 01:10","pubTimestamp":1783617000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GH/analyst-ratings(END) Dow Jones NewswiresJuly 09, 2026 13:10 ET","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4551","BK4588","EKG","LFSC","PTH","GH","GNOM","HELX","LU0889565916.HKD","BK4535","LU0109394709.USD","LU0320765992.SGD","GDOC","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650975065","title":"Analysts Are Bullish on These Healthcare Stocks: Natera (NTRA), Ionis Pharmaceuticals (IONS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2650975065","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650975065?lang=en_us&edition=fundamental","pubTime":"2026-07-10 00:50","pubTimestamp":1783615808,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Natera (NTRA) and Ionis Pharmaceuticals (IONS) with ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-natera-ntra-ionis-pharmaceuticals-ions-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-natera-ntra-ionis-pharmaceuticals-ions-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0345770993.USD","LU0345770308.USD","NTRA","GNOM","LU0106261612.USD","LU0012050646.USD","LU2065731478.USD","LU0963586101.USD","LU2065170008.USD","LU2264538146.SGD","LU2065169927.USD","LU0053671581.USD","IONS","LU1988902786.USD","BK4139","LU2065171402.SGD","HELX","LU1064131342.USD","LU2065171311.SGD","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650975200","title":"Adaptive Biotechnologies is Maintained at Equal-weight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2650975200","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650975200?lang=en_us&edition=fundamental","pubTime":"2026-07-10 00:49","pubTimestamp":1783615740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ADPT/analyst-ratings(END) Dow Jones NewswiresJuly 09, 2026 12:49 ET","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HELX","ADPT","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650978431","title":"Natera Shares Gain 2.8% After EU Certification for Cancer Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2650978431","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650978431?lang=en_us&edition=fundamental","pubTime":"2026-07-09 23:00","pubTimestamp":1783609205,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nFWN43B16H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0345770993.USD","LU0963586101.USD","LU2065171311.SGD","GNOM","LU2324357040.USD","HELX","LU1988902786.USD","BK4139","LU0012050646.USD","LU2065170008.USD","LU2065731478.USD","LU0106261612.USD","NTRA","LU0053671581.USD","LU2065169927.USD","LU0345770308.USD","LU2264538146.SGD","LU2065171402.SGD","LU1064131342.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650922672","title":"How New Signatera Colorectal Data and Trial Deals Could Shape Natera’s (NTRA) Long-Term Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2650922672","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650922672?lang=en_us&edition=fundamental","pubTime":"2026-07-09 19:43","pubTimestamp":1783597418,"startTime":"0","endTime":"0","summary":"Natera recently reported that Monica Bertagnolli resigned from its board due to her new role at the National Academy of Medicine and highlighted fresh JAMA Oncology and ESMO GI data showing its Signatera MRD test can help guide adjuvant chemotherapy decisions and prognostication in resected colorectal liver metastases, while also announcing new Prospera and Signatera clinical trial partnerships.\nThis combination of strengthened clinical evidence and expanded trial integrations for Natera’s...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/how-new-signatera-colorectal-data-and-trial-deals-could-shap","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/how-new-signatera-colorectal-data-and-trial-deals-could-shap","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2065169927.USD","LU0963586101.USD","LU0345770993.USD","LU0106261612.USD","LU0012050646.USD","BK4139","LU2065170008.USD","LU0345770308.USD","GNOM","NTRA","LU2065171311.SGD","LU2264538146.SGD","LU2065171402.SGD","LU1064131342.USD","LU1988902786.USD","LU2065731478.USD","LU0053671581.USD","HELX","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650929872","title":"Ligand Pharmaceuticals : Bofa Global Research Raises Price Objective to $388.00 from $266.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2650929872","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650929872?lang=en_us&edition=fundamental","pubTime":"2026-07-09 19:31","pubTimestamp":1783596687,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nAZN4T6TU5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LGND","IE0009354923.USD","BK4139","HELX","LU1559883803.SGD","BK4007","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650926335","title":"Adaptive Biotechnologies price target raised to $20 from $18 at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2650926335","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650926335?lang=en_us&edition=fundamental","pubTime":"2026-07-09 19:00","pubTimestamp":1783594849,"startTime":"0","endTime":"0","summary":"Morgan Stanley raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $20 from $18 and keeps an Equal Weight rating on the shares. Th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/adaptive-biotechnologies-price-target-raised-to-20-from-18-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/adaptive-biotechnologies-price-target-raised-to-20-from-18-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADPT","BK4121","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650893926","title":"Guardant Health price target raised to $175 from $130 at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2650893926","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650893926?lang=en_us&edition=fundamental","pubTime":"2026-07-09 19:00","pubTimestamp":1783594833,"startTime":"0","endTime":"0","summary":"Morgan Stanley raised the firm’s price target on Guardant Health (GH) to $175 from $130 and keeps an Overweight rating on the shares. The firm is u...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guardant-health-price-target-raised-to-175-from-130-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guardant-health-price-target-raised-to-175-from-130-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0889565916.HKD","BK4535","LU0109394709.USD","GNOM","BK4551","LFSC","PTH","BK4196","HELX","LU0320765992.SGD","GDOC","GH","BK4588","BK4585","EKG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650923734","title":"Ligand price target raised to $388 from $266 at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2650923734","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650923734?lang=en_us&edition=fundamental","pubTime":"2026-07-09 18:20","pubTimestamp":1783592426,"startTime":"0","endTime":"0","summary":"BofA analyst Jason Zemansky raised the firm’s price target on Ligand (LGND) to $388 from $266 and keeps a Buy rating on the shares. Despite strong ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ligand-price-target-raised-to-388-from-266-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ligand-price-target-raised-to-388-from-266-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LGND","BK4139","LU1559883803.SGD","LU0566484027.USD","IE0009354923.USD","HELX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650923368","title":"Natera Announces Ivdr Certification for Signatera™ Across Multiple Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2650923368","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650923368?lang=en_us&edition=fundamental","pubTime":"2026-07-09 18:05","pubTimestamp":1783591510,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nFWN43A1AG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HELX","LU0345770308.USD","LU2065171402.SGD","LU2065170008.USD","LU1064131342.USD","LU2065731478.USD","LU2264538146.SGD","LU0106261612.USD","BK4139","LU2324357040.USD","LU0963586101.USD","LU2065169927.USD","LU0012050646.USD","LU1988902786.USD","GNOM","LU0345770993.USD","LU2065171311.SGD","LU0053671581.USD","NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650056928","title":"Natera’s Signatera MRD Test Wins EU IVDR Certification for Multiple Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2650056928","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650056928?lang=en_us&edition=fundamental","pubTime":"2026-07-09 18:00","pubTimestamp":1783591250,"startTime":"0","endTime":"0","summary":"Natera’s Signatera MRD test wins EU IVDR certification for multiple cancersNatera secured EU IVDR certification for its Signatera cancer test as a Class C in vitro diagnostic device.The clearance supp","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nNDL2XxP7V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HELX","NTRA","LU0012050646.USD","LU2065169927.USD","BK4139","LU2065170008.USD","LU0963586101.USD","LU0345770308.USD","LU0053671581.USD","LU2065731478.USD","LU0106261612.USD","LU2264538146.SGD","LU2065171311.SGD","LU2065171402.SGD","GNOM","LU0345770993.USD","LU1988902786.USD","LU2324357040.USD","LU1064131342.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650102912","title":"Natera Executive Chairman Matthew Rabinowitz Reports Disposal of 1,000 Common Shares Worth $280,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2650102912","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650102912?lang=en_us&edition=fundamental","pubTime":"2026-07-09 09:05","pubTimestamp":1783559134,"startTime":"0","endTime":"0","summary":"Natera Executive Chairman Matthew Rabinowitz reports disposal of 1,000 common shares worth $280,000Natera Executive Chairman Matthew Rabinowitz reported a sale of 1,000 common shares at $280 on July 6","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nNDL4BDSsW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Natera Executive Chairman Matthew Rabinowitz Reports Disposal of 1,000 Common Shares Worth $280,000","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0345770993.USD","LU0106261612.USD","LU2065171402.SGD","LU1988902786.USD","LU0963586101.USD","LU2065170008.USD","LU2264538146.SGD","HELX","LU2065169927.USD","NTRA","LU0345770308.USD","GNOM","LU0053671581.USD","LU0012050646.USD","LU2324357040.USD","LU1064131342.USD","LU2065731478.USD","BK4139","LU2065171311.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650999712","title":"Guardant Health is Maintained at Buy by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2650999712","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650999712?lang=en_us&edition=fundamental","pubTime":"2026-07-09 00:15","pubTimestamp":1783527300,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GH/analyst-ratings(END) Dow Jones NewswiresJuly 08, 2026 12:15 ET","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4551","BK4588","EKG","LFSC","PTH","GH","GNOM","HELX","LU0889565916.HKD","BK4535","LU0109394709.USD","LU0320765992.SGD","GDOC","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649896075","title":"Ligand Pharmaceuticals Inc : Stifel Raises Target Price to $332 from $255","url":"https://stock-news.laohu8.com/highlight/detail?id=2649896075","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649896075?lang=en_us&edition=fundamental","pubTime":"2026-07-08 18:59","pubTimestamp":1783508366,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260708:nFWN43A0MT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LGND","HELX","BK4139","IE0009354923.USD","LU1559883803.SGD","LU0566484027.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649296091","title":"Guardant Health price target raised to $215 from $150 at Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2649296091","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649296091?lang=en_us&edition=fundamental","pubTime":"2026-07-08 18:45","pubTimestamp":1783507510,"startTime":"0","endTime":"0","summary":"Citi analyst Patrick Donnelly raised the firm’s price target on Guardant Health (GH) to $215 from $150 and keeps a Buy rating on the shares. Publis...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guardant-health-price-target-raised-to-215-from-150-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guardant-health-price-target-raised-to-215-from-150-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PTH","EKG","HELX","GH","LFSC","GNOM","LU0320765992.SGD","BK4585","BK4551","BK4196","BK4535","GDOC","LU0889565916.HKD","LU0109394709.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649953160","title":"Adaptive Biotech CSO Harlan S. Robins Disposes of USD 8.49 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2649953160","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649953160?lang=en_us&edition=fundamental","pubTime":"2026-07-08 06:53","pubTimestamp":1783464813,"startTime":"0","endTime":"0","summary":"Adaptive Biotech CSO Harlan S. Robins disposes of USD 8.49 million in common sharesAdaptive Biotechnologies Chief Scientific Officer Harlan S. Robins sold 386,240 common shares on July 2, 2026.Sales p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nNDLt6cCv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Adaptive Biotech CSO Harlan S. Robins Disposes of USD 8.49 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HELX","BK4121","ADPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649670282","title":"Natera President, Clinical Diagnostics Solomon Moshkevich Disposes of USD 819,636 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2649670282","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649670282?lang=en_us&edition=fundamental","pubTime":"2026-07-07 09:05","pubTimestamp":1783386344,"startTime":"0","endTime":"0","summary":"Natera President, Clinical Diagnostics Solomon Moshkevich disposes of USD 819,636 in common sharesNatera President, Clinical Diagnostics Solomon Moshkevich sold 3,000 common shares on July 1.Sales pri","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nNDL2PMv9D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Natera President, Clinical Diagnostics Solomon Moshkevich Disposes of USD 819,636 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNOM","LU0345770993.USD","HELX","LU0012050646.USD","LU2065171402.SGD","LU1988902786.USD","LU2065170008.USD","LU2324357040.USD","LU0053671581.USD","LU0106261612.USD","LU2065169927.USD","LU2065731478.USD","LU0345770308.USD","LU2264538146.SGD","LU0963586101.USD","LU1064131342.USD","LU2065171311.SGD","BK4139","NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649670565","title":"Does Russell Index Removal Reshape the Bull Case for Adaptive Biotechnologies (ADPT)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2649670565","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649670565?lang=en_us&edition=fundamental","pubTime":"2026-07-07 08:32","pubTimestamp":1783384360,"startTime":"0","endTime":"0","summary":"On 27 June 2026, Adaptive Biotechnologies Corporation was removed from several Russell indices, including the Russell 3000E, Russell 3000E Growth Benchmark, Russell Microcap Index and Russell Microcap Growth Benchmark Index.\nThis broad index removal can alter how index-linked and institutional investors hold or trade Adaptive Biotechnologies, potentially reshaping the stock’s investor base and liquidity profile.\nWe’ll now examine how Adaptive Biotechnologies’ removal from multiple Russell...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/does-russell-index-removal-reshape-the-bull-case-for-adaptiv","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/does-russell-index-removal-reshape-the-bull-case-for-adaptiv","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ADPT","HELX","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649672129","title":"Adaptive Biotechnologies CCO Susan Bobulsky Sells 487 Shares Worth $10,714","url":"https://stock-news.laohu8.com/highlight/detail?id=2649672129","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649672129?lang=en_us&edition=fundamental","pubTime":"2026-07-07 07:16","pubTimestamp":1783379802,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies CCO Susan Bobulsky sells 487 shares worth $10,714Adaptive Biotechnologies Chief Commercial Officer, MRD Susan Bobulsky sold 487 common shares on July 1 at USD 22.Bobulsky held","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nNDL4Vrgp2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Adaptive Biotechnologies CCO Susan Bobulsky Sells 487 Shares Worth $10,714","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADPT","BK4121","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649746406","title":"Ligand CLO, Secretary Andrew Reardon Disposes of Common Shares Worth $1.53 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2649746406","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649746406?lang=en_us&edition=fundamental","pubTime":"2026-07-07 05:12","pubTimestamp":1783372345,"startTime":"0","endTime":"0","summary":"Ligand CLO, Secretary Andrew Reardon disposes of common shares worth $1.53 millionLigand Pharmaceuticals CLO and Secretary Andrew Reardon reported net sales of 5,000 common shares on July 1, 2026 unde","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nNDL8PXf1Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Ligand CLO, Secretary Andrew Reardon Disposes of Common Shares Worth $1.53 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGND","HELX","BK4139","IE0009354923.USD","LU1559883803.SGD","LU0566484027.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":10,"totalSize":200,"code":"91000000","status":"200"}]}}